Related Experiment Video
Updated: Aug 19, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy
I W Birchall1, Z Lalani, P Venner
1Department of Oncologic Imaging, Cross Cancer Institute, Edmonton, Alberta, Canada.
Insights
Cyclophosphamide therapy can cause rare hemorrhagic myocarditis. Echocardiography can identify this condition, and its ultrasound features are reported here for the first time.
Area of Science:
- Cardiology
- Oncology
- Toxicology
Background:
- Cyclophosphamide is a widely used chemotherapy agent.
- Hemorrhagic myocarditis is a rare but serious adverse effect of cyclophosphamide.
- Early identification of this complication is crucial for patient management.
Observation:
- The study reports on a case of hemorrhagic myocarditis.
- Echocardiography was used to diagnose the condition.
- Specific ultrasound features were observed in this patient.
Findings:
- Echocardiography can effectively identify hemorrhagic myocarditis.
- The ultrasound characteristics of cyclophosphamide-induced hemorrhagic myocarditis were documented.
- These findings represent the first reported ultrasound features of this specific complication.
Implications:
- This study highlights the importance of echocardiography in diagnosing cyclophosphamide-induced hemorrhagic myocarditis.
- Awareness of these ultrasound findings can aid clinicians in early detection.
- Further research may explore the prognostic value of these echocardiographic features.
Abstract:
Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy. Echocardiographic identification of the disorder can be made. We believe that the ultrasound features of this disorder have not been previously reported.
Related Concept Videos
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Rheumatic Heart Disease I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy